A decade on from a landmark genetic-sequencing study, promised progress on typhoid fever has not materialized, says Stephen Baker.
endemic to low-and middle-income countries -are depressingly obvious. Affected people simply do not have the clout to force the scientific community to build on laboratory research.
There are no advocacy groups for typhoid and other diseases of poverty similar to those that exist for HIV. Affected people and communities are not powerful constituencies. Decision-makers in endemic countries are typically drawn from the wealthier classes, and few have had typhoid fever, or have known someone who has died from the disease.
The position of major international donors -including the Bill & Melinda Gates Foundation in Seattle, Washington, and the US National Institutes of Health in Bethesda, Maryland -does not help. They focus on a narrowing range of diseases such as malaria and tuberculosis: priorities typically determined by metrics and disease league tables. Anything else is left mostly untouched.
It can be a vicious circle. Take diagnosis: there is still no good way to detect typhoid, so global estimates of the extent of the problem are based on guesswork and are almost certainly under estimates. The disease thus has low priority in international assessments. Genome-based diagnostic methods are being explored, yet they rarely reach the field -partly because they are designed for use in well funded, technologically advanced laboratories. Academic funding focuses on research, with little left to support development and testing in endemic locations. Many methods simply die before testing, or as a consequence of trials poorly executed on shoestring budgets. We need a new approach. Scientists who fight diseases such as typhoid through laboratory research must work more closely with those of us who do the same in the field.
Funding agencies that support investigators who use genomics research must give them more opportunities to see the nature of the infection in endemic countries. One way is to increase support for consortia and collaborations that already aim to bridge the geographical and technological gap.
Such initiatives also require more support and advocacy from ministries of health in developing countries, to welcome international collaboration and make possible academic and public-health partnerships.
If these crucial issues are not addressed, I fear that the sequence of the S. enterica Typhi genome, and others like it, will persist as a fascinating academic advance, mostly useless in a public-health context. ■ 
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